Small molecule inhibitors of G9a reactivate the maternal PWS genes in Prader-Willi-Syndrome patient derived neural stem cells and differentiated neurons
H. Wu, C. Ng, V. Villegas, S. Chamberlain, A. Cacace, O. Wallace
Abstract
Abstract/SummaryPatients with Prader-Willi-Syndrome (PWS) display intellectual impairment, hyperphagia, and various behavioral problems during childhood that converge on a neurologic deficit. The majority of PWS patients have genetic deletions of the paternal 15q11-q13 chromosomal region, with their maternal PWS locus intact but epigenetically silenced by hypermethylation and repressive histone modulation of the PWS imprinting center (PWS-IC). Inhibition of the euchromatin histone methyltransferase G9a by small molecules has been recently reported to reactivate PWS genes in patient fibroblasts and a mouse model. However, it is unknown if inhibition of G9a could have similar effect in human PWS neural cells, the cell types that have direct pathophysiological relevance to PWS. Here, we use neural progenitor cells (NPCs) and cortical excitatory neurons derived from a patient iPSC to model PWS, and quantitatively profile the expression of PWS genes using a NanoString panel. We demonstrated that the methylation of the PWS-IC is stable during neuronal lineage conversion, and that the maternal PWS genes remain silenced in PWS NPCs and neurons. Multiple small molecule inhibitors of G9a activate maternal PWS genes in a dose dependent manner in both NPCs and neurons. In addition, G9a inhibitors induce GNRH1 and HTR2C, two neuronal specific genes that contribute to PWS pathology in neurons. Interestingly, distinct from 5-Azacytidine, G9a inhibition does not induce methylation changes of the maternal PWS-IC, indicating that disruption of the histone repressive complex alone is sufficient to drive an open chromatin state at the PWS-IC that leads to partial reactivation of PWS genes. HighlightsO_LIModeling PWS disease in a dish using patient derived NPCs and neurons C_LIO_LIG9a inhibition activates maternal PWS genes in patient-derived neural cells C_LIO_LIG9a inhibition activates maternal SNORD116 and other PWS genes in patient-derived neurons C_LIO_LIInhibition of G9a induces PWS downstream genes GNRH1 and HTR2C in PWS neurons C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Specific ZNF274 binding interference at SNORD116 activates the maternal transcripts in Prader-Willi syndrome neurons
Maéva Langouët, Dea Gorka, … Stormy J. Chamberlain·Human Molecular GeneticsPeer-reviewed·Sep 18, 2020
- SMCHD1 is a novel target for gene-activation therapy to treat Prader-Willi Syndrome
Megan Iminitoff, Anna K. Le Fevre, … Marnie E. Blewitt·bioRxiv·May 14, 2026
- Non-coding RNAs Associated with Prader-Willi Syndrome Regulate Transcription of Neurodevelopmental Genes in Human Induced Pluripotent Stem Cells
Monika Śledziowska, Kinga Winczura, … Pawel Grzechnik·Human Molecular GeneticsPeer-reviewed·Jan 1, 2021
- Identifying key underlying regulatory networks and predicting targets of orphan C/D box SNORD116 snoRNAs in Prader-Willi syndrome
Rachel B. Gilmore, Yaling Liu, … Justin L. Cotney·Nucleic Acids ResearchPeer-reviewed·Nov 22, 2024
- Activation of the imprinted Prader-Willi Syndrome locus by CRISPR-based epigenome editing
Dahlia Rohm, Joshua B. Black, … Charles A. Gersbach·Cell GenomicsPeer-reviewed·Feb 1, 2025
- Investigation of a Novel Mouse Model of Prader-Willi Syndrome with Invalidation of Necdin and Magel2
Pierre-Yves Barelle, Alicia Sicardi, … Françoise Muscatelli·bioRxiv·Jul 24, 2024